BTK Inhibitors Continue to Improve Survival in Mantle Cell Lymphoma
Michael Wang, MD, discusses the role of BTK inhibitors as treatment of patients with mantle cell lymphoma ahead of his presentation at the 2020 SOHO Annual Meeting.
Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the role of BTK inhibitors as treatment of patients with mantle cell lymphoma (MCL) ahead of his presentation at the 2020 SOHO Annual Meeting.
Wang believes the overall survival of patients with MCL will continue to be prolonged. The first approved targeted treatment option in MCL was bortezomib (Velcade), which presented with an objective response rate (ORR) of 32%. Lenalidomide (Revlimid) was the second drug to be approved a few years later in 2013, which had an ORR of 25%.
Ibrutinib (Imbruvica) was later approved for the treatment of patients with MCL. Wang says he had the honor of leading the clinical trial that led to this agent’s approval, which had an ORR of 68% and a complete response rate of 20%. Several years later, acalabrutinib (Calquence) was also approved, which had great survival outcomes as well. Zanubrutinib (Brukinsa) was approved by the FDA, marking the third BTK inhibitor approved for the treatment of MCL.
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
